N/A N=30 Seprafilm in Open Abdomens: a Study of Wound and Adhesion Characteristics in Trauma Damage Control Patients
Open Abdomen · Abdominal Adhesions · Trauma
Primary: Adhesion Characteristics — 1.06; 1.08; 1.13; 1.08 Scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=329 BIOHELIX-I Bare Metal Stent Study
Coronary Arteries Disease
Primary: Target Vessel Failure Rate — 9.06; 0.95; 1.58; 7.26 Percentage of participants
Phase 4 N=279 Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes
Type 2 Diabetes
Primary: Mean Blood Glucose Concentration After First Day of Treatment — 9.5; 9.4 mmol/L
Phase 2 N=68 Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Prostatic Neoplasm · Prostate Cancer · Prostatic Adenocarcinoma
Primary: Immune Response at Month 24 as Evaluated by IFN-γ ELISPOT Specific for PA2024 — 81.0; 61.1 IFN-γ ELISPOT (per 300,000 PBMC)
N/A N=20 Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B
Healthy
Primary: Quantification of Plasma Lipids in the Whole Blood: Prostaglandin E2 (PGE2) — 49.9; 110 percentage of pre-dose control
Phase 2 N=72 Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain
Opioid Induced Bowel Dysfunction
Primary: Number of Participants With Adverse Events — 9; 6; 6; 5 participants
Phase 3 N=20 Azelaic Acid on Demodex Counts in Rosacea
Rosacea
Primary: Demodex Count — 40; 18 number of demodex
Phase 2 N=18 Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Colon Mucinous Adenocarcinoma · Colon Signet Ring Cell Adenocarcinoma · Rectal Mucinous Adenocarcinoma
Primary: Overall Response Rate (CR+PR) Evaluated Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 0 Participants
Phase 2 N=199 LY353381 in Preventing Breast Cancer in Women With Hyperplasia
Breast Cancer
Primary: Change in Masood Score — -1.1; -0.8 units on a scale
N/A N=34 Post-Traumatic Stress Disorder (PTSD) and Seroquel
Post-Traumatic Stress Disorder
Primary: Change From Baseline in PTSD Symptomatology at the Week 8 Timepoint. — 7.3 units on a scale
Phase 3 N=100 Combined Medication for Improved Analgesia in Superficial Pain
Pain
Primary: Pain Scores on Standardized Experimental Pain Testing — 59.6; 54.0; 44.1; 45.3 units on a scale
Phase 2 N=71 Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Treatment-related Mortality — 8.4 percentage of participants
Phase 3 N=769 Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss
Cancer · Cataract · Low Bone Mineral Density
Primary: Percentage of Participants With Lens Opacification Event Development or Progression by Month 12 — 33.2; 33.5 percentage of participants — p=0.0026
Phase 2 N=12 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Acute Undifferentiated Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Incidence of Grade III-IV Acute GVHD — 25 percentage of participants
N/A N=84 Safety and Effectiveness of Wavefront-guided LASIK for the Correction of Mixed Astigmatism
Astigmatism
Primary: Line Loss of More Than Two Lines for Best Spectacle Corrected Visual Acuity (BSCVA) — 149 eyes